FDA OKs Phase 1 Trial to Test Celyad’s Donor-derived CAR T-cell Therapy in Colorectal Cancer

관련뉴스

1. Celyad’s CAR T-Cell Therapy, CYAD-01, Showing Early Signs of Efficacy in Advanced Colorectal Cancer CYAD-01 — Celyad‘s CAR T-cell product — is showing promise as a treatment for metastatic colorectal cancer patients (mCRC), both alone and in combination with standard of care chemotherapy, according to findings from two clinical trials. These … (본문 전체 11/20/2018 10:08 PM)...
   
   
2. Celyad’s Donor Cell CAR-T Therapy Gets Closer to the Clinic Celyad has received FDA approval to start clinical trials for its CAR-T cell therapy, which is engineered to avoid side effects associated with using donor cells for this kind of treatment. The Belgian biotech has been cleared to test its CAR-T cell … Date : 2018-07-24T08:00:00.000Z Source : https://labiotech.eu/medical/celyad-car-t-therapy-clinic/...
   
   
3. Lion TCR T-cell therapy for liver cancer to undergo phase 1/2 trial Lion TCR received approval from the Health Sciences Authority in Singapore to perform a phase 1/2 multicenter clinical study of its LioCyx candidate for treating liver cancer relapse after liver transplant, according to a press release. “We are very … (본문 전체 8/21/2018 4:36 AM)...
   
   
4. Belgian Biotech to Abandon Phase III Cell Therapy Trial for Bone Disease Bone Therapeutics is going to discontinue its cell therapy Phase III trial after finding little hope of success for patients with the bone disease osteonecrosis. If all had gone as planned, the full trial would have monitored 118 patients over 24 months. (본문 전체 11/7/2018 5:00 PM)...
   
   
5. A cancer therapy developed at a CIRM Alpha Stem Cell Clinic tests its legs against breast cancer A Phase 1 clinical trial co-sponsored by CIRM and Oncternal Therapeutics, has started treating patients at UC San Diego (UCSD). The goal of the trial is to test the safety and anti-tumor activity of the Oncternal-developed drug, cirmtuzumab, in treating … (본문 전체 9/18/2018 1:35 AM)...
   
   
6. Phase 2 Trial of NurOwn Stem Cell Therapy in Progressive MS Planned for US, BrainStorm Announces BrainStorm Cell Therapeutics is planning to launch a Phase 2 clinical trial in the United States to evaluate the safety and activity of its lead cell therapy candidate, NurOwn, in people with … (본문 전체 11/21/2018 10:17 PM)...
   
   
7. Cancer Patients with Rare Deadly Brain Infection Treated Successfully with Off-the-Shelf Adoptive T-Cell Therapy in Clinical Trial Newswise — An emerging treatment known as adoptive T-cell therapy has proven effective in a Phase II clinical trial for treating progressive multifocal leukoencephalopathy (PML), a rare and often fatal brain infection sometimes observed in patients with … (본문 전체 10/11/2018 6:10 AM)...
   
   
8. Cell therapy for knee cartilage damage did not meet primary endpoint in phase 3 trial Histogenics Corporation announced in a press release that the phase 3 clinical trial of its restorative cell therapy NeoCart did not meet its primary endpoint of statistically significant improvement in pain and function 1 year after treatment compared … (본문 전체 9/27/2018 4:12 AM)...
   
   
9. Pluristem Therapeutics unveils positive results from early stage clinical trial for its placenta-derived cell therapy Israeli biotech company Pluristem Therapeutics (NASDAQ:PSTI) on Wednesday unveiled favorable data from a Phase 1/2 clinical trial evaluating its placenta-derived cell therapy product, PLX-PAD, for the treatment of muscle injury after hip replacement surgery. (본문 전체 10/10/2018 11:01 PM)...
   
   
10. Cancer therapy: Bacteria may help shrink tumors scientists are now experimenting with a modified bacterial strain that could target cancer cells without harming healthy ones. A phase I clinical trial reveals that this bacterial therapy shows promising effects. A team at the University of Texas MD … (본문 전체 10/4/2018 5:19 AM)...
    
    
11. Phase I clinical trial shows safety and tolerability of HIV-specific, ex-vivo expanded T-cell therapy Preliminary results from a phase I clinical trial have demonstrated the safety and tolerability of a cell therapy involving the ex vivo expansion of T cells and their subsequent infusion into HIV-infected individuals previously treated with antiretroviral … (본문 전체 9/24/2018 8:32 PM)...
    
    
12. T-cell Therapy Showing Promise in Synovial Sarcoma Patients in Phase 1 Trial A2M4, an investigational therapy that uses engineered immune cells to fight cancer, showed an acceptable safety profile and promising effectiveness in people with synovial sarcoma, a rare cancer that develops around the joints and tendons, [전체본문 2021-01-16 03:51:00Z]...
    
    
13. Mesoblast defends stem cell therapy for heart failure after trial miss Mesoblast’s stem cell-based therapy was unable to reduce heart failure (HF) patients’ reliance on a left ventricular assist device (LVAD) in a phase 2 trial, sparking a steep slide in its shares. The Australian biotech said the trial showed that … (본문 전체 11/13/2018 11:08 PM)...
    
    
14. Preclinical research: CAR T cell therapy effective against HER2-positive breast cancer with brain metastasis Patients with HER2-positive breast cancer need more treatment options — today, it is estimated that about half of all women with HER2-positive breast cancer will eventually develop brain metastases, and current therapies for these patients are limited. (본문 전체 8/4/2018 8:10 AM)...
    
    
15. Global Cancer Gene Therapy Market Opportunity Assessment|Key Players: Sibiono Genetech, Human Stem Cell Institute, Altor Bioscience Corporation, Amgen Global Cancer Gene Therapy to exceed USD 4 billion by 2024 as per a new research report. Robust research and development in the field of cancer gene therapy aimed at finding cure for rare genetic cancer will drive the market growth over forecast timeframe. (본문 전체 10/6/2018 6:26 PM)...
    
    
16. Trial to assess CAR T-cell therapy for certain lymphomas, leukemias Researchers are launching a first-in-human clinical trial to assess the use of chimeric antigen receptor T-cell therapy targeting the CD4 protein among patients with relapsed and refractory T-cell lymphoma and leukemia. Huda S. Salman, MD, oncologist at … (본문 전체 11/28/2018 3:55 AM)...
    
    
17. Imara’s Sickle Cell Disease Therapy Impresses in Phase 2 Trial Boston-based biotech, Imara Inc. announced promising Phase2a trial results of its Sickle Cell Disease Drug, IMR-687. When compared to the placebo, IMR-687 was well tolerated as a [전체본문 2021-01-09 04:05:00Z]...
    
    
18. Good Results From Trial of CAR T Cell Therapy for Non-Hodgkin Lymphoma Researchers have reported positive results from a phase 2 clinical trial of a CAR T cell therapy called axicabtagene ciloleucel (axi-cel) | Cell And Molecular Biology [전체본문 2021-01-05 00:40:00Z]...
    
    
19. CAR-T cell therapy used as treatment for specific types of blood cancer DEAR MAYO CLINIC: What is chimeric antigen receptor T cell (CAR-T cell) therapy? How does it work to treat cancer, and who’s a good candidate for it? ANSWER: CAR-T cell therapy uses white blood cells, called T cells, to fight cancer. It’s approved by … (본문 전체 12/6/2018 3:05 AM)...
    
    
20. Stem cell therapy developed at UW-Madison tested in clinical trial The first stem cell therapy developed at UW-Madison to enter a clinical trial was found to be safe and beneficial to patients, according to the company overseeing the experimental treatment. In a phase 1 trial, concluded this year, 15 patients received the … (본문 전체 11/4/2018 9:06 PM)...